Arcutis Biotherapeutics, Inc.
ARQT
株式のランク
#3982
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to... Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
株価
$32.88
最終同期: 2026-10-20
時価総額
$4.13B
変化（1日）
3.11%
変化（1年）
59.32%
国
US
取引 Arcutis Biotherapeutics, Inc. (ARQT)
カテゴリー
Healthcare
Arcutis Biotherapeutics, Inc.（ARQT）の収益
Jun 2026 時点の収益 TTM: $463.98M
Arcutis Biotherapeutics, Inc. の最新の財務報告によると、現在の収益 (TTM) は $463.98M です。2023 年には $59.61M の収益があり、これは 2022 年の $3.69M と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Arcutis Biotherapeutics, Inc. の収益履歴（2017 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $463.98M | 136.07% |
| 2024 | $196.54M | 229.74% |
| 2023 | $59.61M | 1,517.09% |
| 2022 | $3.69M | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $12.62B | 2,620.87% |
US
|
|
| $2.23B | 380.19% |
US
|
|
| $15.74B | 3,293.31% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 1,197.74% |
NL
|
